AVITA Medical, Inc. RCEL

About AVITA Medical, Inc. (RCEL): stock profile, AI score and financials

AVITA Medical, Inc. (RCEL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RCEL at 28.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,535 of 2,925 stocks — the bottom half of the AI-ranked universe. RCEL scores in the top quartile across revenue growth (78.4). Areas of concern include balance sheet strength (1.5) and profitability (10.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), AVITA Medical, Inc. reports quarterly revenue of $21.7M, net income of $-7.7M, an operating margin of -31.6%. Top institutional holders of RCEL by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. RCEL trades on the Nasdaq exchange and files with the SEC under CIK 1762303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RCEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVITA Medical, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1762303 →